Taking aim at HDL-C: Raising levels to reduce cardiovascular risk

Postgraduate Medicine

Volumn 117, Issue 4, 2005, Pages 29-44

  Mcgovern, Mark E ^a  

^a Kos Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; CHOLESTEROL ESTER TRANSFER PROTEIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; SIMVASTATIN; STATINE DERIVATIVE; VACCINE; HYPOCHOLESTEROLEMIC AGENT;

ATHEROGENESIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; CONFERENCE PAPER; DRUG TARGETING; EVIDENCE BASED MEDICINE; HEART INFARCTION; HEART PROTECTION; HUMAN; ISCHEMIC HEART DISEASE; RISK REDUCTION; STROKE; BLOOD; CORONARY ARTERY DISEASE; DRUG EFFECT; REVIEW; RISK FACTOR;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CLINICAL TRIALS; CORONARY DISEASE; HUMANS; RISK FACTORS;

EID: 58149181419     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2005.04.1610     Document Type: Article

References (16)

1. Maron DJ. The epidemiology of low levels of high-density lipoprotein cholesterol in patients with and without coronary artery disease. Am J Cardiol 2000; 86 (12A): 11 – 4L
2. Morgan J, Carey C, Lincoff A, et al. High-density lipoprotein subfractions and risk of coronary artery disease. Curr Atheroscler Rep 2004; 6 (5): 359 – 65
3. Sacks FM; Expert Group on HDL Cholesterol. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol 2002; 90 (2): 139 – 43
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285 (19): 2486 – 97
5. Bays HE. Extended-release niacin/lovastatin: the first combination product for dyslipidemia. Expert Rev Cardiovasc Ther 2004; 2 (4): 485 – 501
6. Wilt TJ, Bloomfield HE, MacDonald R, et al. Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med 2004; 164 (13): 1427 – 36
7. Brewer HB Jr, Remaley AT, Neufeld EB, et al. Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease. Arterioscler Thromb Vase Biol 2004; 24 (10): 1755 – 60
8. Bays H, Stein EA. Pharmacotherapy for dyslipidaemia—current therapies and future agents. Expert Opin Pharmacother 2003; 4 (11): 1901 – 38
9. Brown BG, Zhao X-Q, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345 (22): 1583 – 92
10. Kashyap ML, Tavintharan S, Kamanna VS. Optimal therapy of low levels of high density lipoprotein-cholesterol. Am J Cardiovasc Drugs 2003; 3 (1): 53 – 65
11. Mosca L, Appel LJ, Benjamin EJ, et al; American Heart Association. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation 2004; 109 (5): 672 – 93
12. American Diabetes Association Position Statement. Dyslipidemia management in adults with diabetes. Diabetes Care 2004; 27 (Suppl 1): S68 – 71
13. Chapman MJ, Assmann G, Fruchart JC, et al; European Consensus Panel on HDL-C. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid—a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 2004; 20 (8): 1253 – 68
14. Guyton JR. Extended-release niacin for modifying the lipoprotein profile. Expert Opin Pharmacother 2004; 5 (6): 1385 – 98
15. Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004; 110 (23): 3512 – 7
16. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003; 290 (17): 2292 – 300